Skip to main content
Glama

Metabolights

by io.github.pipeworx-io

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.6/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

The description adds substantial behavioral detail beyond the annotations: graceful degradation when GLEIF/OpenFIGI are unavailable, explicit reporting of unresolved identifiers, returning figi_candidates on ambiguity, and multi-endpoint cascade behavior. It also clarifies that non-equity instruments resolve, which is a non-obvious safety property.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is dense and front-loaded with helpful examples and the primary use rule. It is long, but nearly every sentence conveys a distinct and useful fact about resolution behavior, type support, or edge cases. A bit more formatting would improve scannability, but there is no fluff.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness4/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

For a tool with no output schema, the description covers the return behavior well: canonical identifiers, unresolved fields, figi_candidates, source labels, and the drug citation format. It omits a structured response contract, but the narrative coverage is strong enough for an agent to understand what to expect.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100%, but the description still adds significant value: it explains each supported type, gives input format examples, and warns against passing full noun phrases for bonds. The 'ENTITY NAME ONLY' guidance is critical for correct invocation and goes well beyond the schema's terse parameter descriptions.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description opens with concrete user phrasings and states the core purpose: resolving a user-spoken name into the canonical/official identifiers other tools require. It clearly differentiates itself as the first step before other tools and distinguishes between 'company' and 'drug' resolution.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description explicitly says 'Use FIRST whenever you have a name but need an ID,' which gives a clear trigger condition. It does not explicitly enumerate when not to use it versus close siblings like entity_profile or compare_entities, but the stated use-before-others rule and the emphasis on identifier lookup provide solid practical guidance.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Metabolights toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

B3.3/5.0
Disambiguation1/5

The vast majority of tools (e.g., ask_pipeworx, ask_pipeworx_grounded, bet_research, polymarket_arbitrage, etc.) are unrelated to Metabolights and overlap heavily with each other in purpose. Only two tools (get_study and search_studies) are clearly distinct and relevant to the server's stated domain.

Naming Consistency2/5

Tool names are highly inconsistent, mixing snake_case (get_study, search_studies), camelCase (ask_pipeworx), and varied verb styles (e.g., validate_claim vs bet_research). No consistent pattern across the set.

Tool Count1/5

With 28 tools, the server is extremely overpopulated for its stated purpose (Metabolights). Only 2 tools actually pertain to metabolomics study access, while the remaining 26 are general-purpose or unrelated (e.g., bet_research, polymarket_edges), making the count highly inappropriate.

Completeness1/5

The Metabolights domain severely lacks completeness: only search_studies and get_study are provided, with no create, update, delete, or upload functionality. The server fails to cover essential operations for its supposed domain.

Resources